Editas Medicine (EDIT) Free Cash Flow (2016 - 2025)
Historic Free Cash Flow for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to -$31.3 million.
- Editas Medicine's Free Cash Flow rose 4365.6% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$180.7 million, marking a year-over-year increase of 556.66%. This contributed to the annual value of -$219.1 million for FY2024, which is 6005.46% down from last year.
- Per Editas Medicine's latest filing, its Free Cash Flow stood at -$31.3 million for Q3 2025, which was up 4365.6% from -$50.2 million recorded in Q2 2025.
- In the past 5 years, Editas Medicine's Free Cash Flow ranged from a high of -$23.5 million in Q4 2023 and a low of -$60.6 million during Q2 2024
- In the last 5 years, Editas Medicine's Free Cash Flow had a median value of -$43.1 million in 2021 and averaged -$44.1 million.
- As far as peak fluctuations go, Editas Medicine's Free Cash Flow skyrocketed by 4510.8% in 2023, and later tumbled by 11787.06% in 2024.
- Quarter analysis of 5 years shows Editas Medicine's Free Cash Flow stood at -$37.4 million in 2021, then dropped by 14.62% to -$42.9 million in 2022, then soared by 45.11% to -$23.5 million in 2023, then plummeted by 117.87% to -$51.3 million in 2024, then surged by 39.04% to -$31.3 million in 2025.
- Its Free Cash Flow was -$31.3 million in Q3 2025, compared to -$50.2 million in Q2 2025 and -$47.9 million in Q1 2025.